Phase 3 Depressive Clinical Trials

45 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 120 of 45 trials

Recruiting
Phase 3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder

MidazolamDepressive SymptomSevere Depression+14 more
Theresa Jacob, PhD, MPH40 enrolled1 locationNCT06752759
Recruiting
Phase 3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 3

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences200 enrolled30 locationsNCT06963021
Recruiting
Phase 3

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Major Depressive Disorder
Cybin IRL Limited220 enrolled47 locationsNCT06564818
Recruiting
Phase 3

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled205 locationsNCT06559306
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Depressive Disorder, Major
Janssen Research & Development, LLC258 enrolled6 locationsNCT07227454
Recruiting
Phase 3

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 3

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Depressive Disorder, Major
Eli Lilly and Company1,000 enrolled186 locationsNCT07412756
Recruiting
Phase 3

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences550 enrolled45 locationsNCT07196501
Recruiting
Phase 3

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Axsome Therapeutics, Inc.508 enrolled13 locationsNCT07484217
Recruiting
Phase 3

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Major Depressive Disorder
Takeda180 enrolled30 locationsNCT07204314
Recruiting
Phase 3

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 3

Biomarker-guided rTMS for Treatment Resistant Depression

Major Depressive DisorderTreatment Resistant Depression
Weill Medical College of Cornell University348 enrolled2 locationsNCT04041479
Recruiting
Phase 3

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled71 locationsNCT06058039
Recruiting
Phase 3

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Major Depressive DisorderBipolar DepressionSchizophrenia and Related Disorders
Dr. Inge Winter1,254 enrolled1 locationNCT05603104
Recruiting
Phase 3

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder
Neurocrine Biosciences200 enrolled10 locationsNCT06911112
Recruiting
Phase 3

Improving Outcomes in Depression in Primary Care in a Low Resource Setting

DepressionDepressive Disorder
Harvard Medical School (HMS and HSDM)1,500 enrolled1 locationNCT05944926